Skip to main navigation Skip to search Skip to main content

Comparative Proteomic Profiling of Cisplatin-resistant Nasopharyngeal Carcinoma Cell Lines: Novel Biomarkers for Improving Chemotherapy of NPC

  • Parisa Prathaphan
  • , Onrapak Reamtong
  • , Utapin Ngaokrajang
  • , Tavan Janvilisri
  • , Napachanok Mongkoldhumrongkul Swainson
  • , Pichamon Kiatwuthinon
  • Kasetsart University
  • Mahidol University

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)

Abstract

Background/Aim: Nasopharyngeal carcinoma (NPC) originates in the hidden nasopharynx, causing NPC patients to be diagnosed at a late stage and develop drug resistance. Therefore, the identification of drug-resistance biomarkers is indispensable to improve NPC detection and treatment. Hence, this study aimed to identify novel cisplatin-resistance biomarkers using comparative proteomic profiles of cisplatin-resistant (CDDP/NPC) cell lines. Materials and Methods: Two cisplatin-resistant NPC cell lines (CDDP/58F and CDDP/6-10B) were established by a continuous cisplatin treatment. Then, morphology, proliferation, and migration of all NPC cells were evaluated, followed by the examination of protein profiles using 1D in-gel digestion coupled with mass spectrometry. The potential drug-resistance biomarkers were transcriptionally and translationally validated by qPCR and western blotting, respectively. Results: CDDP/5-8F and CDDP/6-10B cells were successfully developed with a resistance index of 8.42 and 2.46, respectively. Furthermore, both CDDP/NPC cells demonstrated relatively altered morphology, retarded growth, and decreased migration. Additionally, the comparative proteomic analysis of CDDP/NPC revealed 92 differentially expressed proteins (DEPs). Specifically, up-regulated DEPs were notably enriched in cellular metabolic processes, while down-regulated DEPs were predominantly enriched in actin filament-based movement, methylation, and programmed cell death. Six up-regulated, namely ALPI, CKB, HMGB1, KHSRP, PDIA4, and STMN1, and three down-regulated proteins, FUBP1, YWHAZ, and PLEC, were validated at the transcriptional level. CKB and FUBP1 were further validated at the translational level and demonstrated corresponding expression levels at both protein and gene levels. Conclusion: Our findings suggest novel biomarkers to indicate cisplatin resistance in NPC, expanding the drug resistance knowledge and paving the way for in-depth mechanism studies in NPC.

Original languageEnglish
Pages (from-to)3507-3522
Number of pages16
JournalAnticancer Research
Volume42
Issue number7
DOIs
Publication statusPublished - Jul 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Nasopharyngeal carcinoma
  • cisplatin
  • differentially expressed proteins
  • drug resistance
  • proteomics

Fingerprint

Dive into the research topics of 'Comparative Proteomic Profiling of Cisplatin-resistant Nasopharyngeal Carcinoma Cell Lines: Novel Biomarkers for Improving Chemotherapy of NPC'. Together they form a unique fingerprint.

Cite this